|
1
|
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
|
Nature
|
2005
|
4.97
|
|
2
|
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events.
|
Nat Biotechnol
|
2008
|
4.46
|
|
3
|
Chondroitinase ABC I from Proteus vulgaris: cloning, recombinant expression and active site identification.
|
Biochem J
|
2005
|
0.99
|
|
4
|
Biochemical characterization of the chondroitinase ABC I active site.
|
Biochem J
|
2005
|
0.95
|
|
5
|
The catalytic machinery of chondroitinase ABC I utilizes a calcium coordination strategy to optimally process dermatan sulfate.
|
Biochemistry
|
2006
|
0.88
|
|
6
|
Unlocking the secrets of syndecans: transgenic organisms as a potential key.
|
Glycoconj J
|
2003
|
0.86
|
|
7
|
Assessment of the quality and structural integrity of a complex glycoprotein mixture following extraction from the formulated biopharmaceutical drug product.
|
J Pharm Biomed Anal
|
2010
|
0.86
|
|
8
|
Heparin and heparan sulfate: analyzing structure and microheterogeneity.
|
Handb Exp Pharmacol
|
2012
|
0.86
|
|
9
|
The structural elucidation of glycosaminoglycans.
|
Methods Mol Biol
|
2009
|
0.82
|
|
10
|
Structural elucidation of the tetrasaccharide pool in enoxaparin sodium.
|
Anal Bioanal Chem
|
2012
|
0.81
|
|
11
|
Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3.
|
Thromb Res
|
2002
|
0.81
|
|
12
|
M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.
|
Thromb Haemost
|
2009
|
0.80
|
|
13
|
Recombinant expression, purification, and biochemical characterization of chondroitinase ABC II from Proteus vulgaris.
|
J Biol Chem
|
2008
|
0.79
|
|
14
|
Heparin oligosaccharide sequence and size essential for inhibition of pulmonary artery smooth muscle cell proliferation.
|
Carbohydr Res
|
2002
|
0.79
|
|
15
|
Mass spectrometric methods for the analysis of heparin and heparan sulfate.
|
Methods Mol Biol
|
2015
|
0.76
|
|
16
|
Synthesis and biological evaluation of a unique heparin mimetic hexasaccharide for structure-activity relationship studies.
|
J Med Chem
|
2014
|
0.76
|
|
17
|
Corrigendum: Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events.
|
Nat Immunol
|
2016
|
0.75
|
|
18
|
Characterization of heparin-protein interaction by saturation transfer difference (STD) NMR.
|
Anal Bioanal Chem
|
2014
|
0.75
|
|
19
|
Corrigendum: Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events.
|
Nat Immunol
|
2016
|
0.75
|
|
20
|
Identification of a novel structure in heparin generated by sequential oxidative-reductive treatment.
|
Anal Chem
|
2012
|
0.75
|
|
21
|
Glycosaminoglycan characterization methodologies: probing biomolecular interactions.
|
Methods Mol Biol
|
2009
|
0.75
|